Results from KEYNOTE-B98: A Phase 1b/2 Study of Pembrolizumab Plus Investigational Agents in Patients with Anti-Pd-(l)1-refractory Extensive-Stage Small-Cell Lung Cancer (ES-SCLC)
CANCER RESEARCH(2024)
AI 理解论文
溯源树
样例
生成溯源树,研究论文发展脉络
Chat Paper
正在生成论文摘要